Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Submits KP415 NDA to the FDA for the Treatment of ADHD
If approved, KemPharm believes that KP415 may address several unmet needs, including earlier onset of action and longer duration of therapeutic effect vs. other available methylphenidate products CELEBRATION, Fla. , March 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results
KP415 NDA Remains on Track for Q1 2020 Submission CELEBRATION, Fla. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update on the KP415 NDA and reported its
Toggle Summary Nasdaq Grants KemPharm’s Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement
KemPharm’s Common Stock Listing Transfers to The Nasdaq Capital Market Effective Today CELEBRATION, Fla. , Jan. 15, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it
Toggle Summary KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital
Principal and Interest Payments on Outstanding Debt in Principal Amount of $77.7M Pushed to March 31, 2021 ; Expected to Extend Cash Runway to New Maturity Date KemPharm Will Host a Conference Call and Live Audio Webcast with Slide Presentation Today, Wednesday, December 18, 2019 , at 8:30 a.m.
Toggle Summary KemPharm Reports Third Quarter 2019 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for  Today, November 14, 2019 , at 5:30 p.m. ET CELEBRATION, Fla. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary
Toggle Summary KemPharm to Report Third Quarter 2019 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 14, 2019 , 5:30 p.m. ET CELEBRATION, Fla. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019
KVK-Tech is Initially Stocking Selected Regions Based on Formulary Access CELEBRATION, Fla. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today provided a commercial update
Toggle Summary KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting
Data Demonstrate that KP415 Can Be Administered without Regard to Food; Can Be Mixed into Foods or Drink CELEBRATION, Fla. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs,
Toggle Summary KemPharm Provides Updates Regarding its Board of Directors
CELEBRATION, Fla. , Sept. 20, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that, on September 18, 2019 , Danny L. Thompson provided notice of his resignation from the
Toggle Summary KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
CELEBRATION, Fla. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.